Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy

Neurology

Volumn 75, Issue 20, 2010, Pages 1817-1824

  Brodie, M J ^a   Lerche, H ^b,i   Gil Nagel, A ^c   Elger, C ^d   Hall, S ^e   Shin, P ^f   Nohria, V ^g   Mansbach, H ^h  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c Unidad Radiocirugia   (Spain)

^d UNIVERSITY OF BONN   (Germany)

^e Neurology RandD and Regulatory Compliance   (United States)

^f Prometheus Therapeutics and Diagnostics   (United States)

^g MERCER UNIVERSITY   (United States)

^h Medivation Inc   (United States)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; FATTY ACID DERIVATIVE; PLACEBO; RETIGABINE;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOCAL EPILEPSY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY PARTIAL EPILEPSY; SOMNOLENCE; UNSPECIFIED SIDE EFFECT;

EID: 78649984382     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181fd6170     Document Type: Article

References (36)

1. Rostock A, Tober C, Rundfeldt C, et al. D-23129: A new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996;23:211-223.
2. Tober C, Rostock A, Rundfeldt C, Bartsch R. D-23129: A potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 1996;303:163-169.
3. Armand V, Rundfeldt C, Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices. Naunyn Schmiedebergs Arch Pharmacol 1999;359:33-39. (Pubitemid 29142567)
4. Armand V, Rundfeldt C, Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. Epilepsia 2000;41:28-33.
5. Srivastava AK, White HS. Retigabine decreases behavioral and electrographic seizures in the lamotrigine-resistant amygdala kindled rat model of pharmacoresistant epilepsy. Epilepsia 2005;46(suppl 8):217.
6. Porter RJ, Nohria V, Rundfeldt C. Retigabine. Neurotherapeutics 2007;4:149-154.
7. Dalby-Brown W, Hansen HH, Korsgaard MPG, Mirza N, Olesen SP. Kv7 channels: Function, pharmacology and channel modulators. Curr Top Med Chem 2006;6:999-1023.
8. Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary cells transfected with human KCNQ2/3 subunits. Neurosci Lett 2000;282:73-76.
9. Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 2005;67:1009-1017.
10. Schenzer A, Friedrich T, Pusch M, et al. Molecular determinants of KCNQ (Kv7) K+channel sensitivity to the anticonvulsant retigabine. J Neurosci 2005;25:5051-5060.
11. Lange W, Geissendörfer J, Schenzer A, et al. Refinement of the binding site and mode of action of the anticonvulsant retigabine on KCNQ K+ channels. Mol Pharmacol 2009; 75:272-280.
12. Delmas P, Brown DA. Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat Rev Neurosci 2005;6:850-862.
13. Maljevic S, Wuttke TV, Lerche H. Nervous system KV7 disorders: Breakdown of a subthreshold brake. J Physiol 2008;586:1791-1801.
14. Biervert C, Schroeder BC, Kubisch C, et al. A potassium channel mutation in neonatal human epilepsy. Science 1998;279:403-406.
15. Singh NA, Charlier C, Stauffer D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns Nat Genet 1998;18:25-29. (Pubitemid 28027874)
16. Charlier C, Singh NA, Ryan SG, et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat Genet 1998;18:53-55.
17. Jentsch TJ, Schroeder BC, Kubisch C, Friedrich T, Stein V. Pathophysiology of KCNQ channels: Neonatal epilepsy and progressive deafness. Epilepsia 2000;41:1068-1069.
18. Neubauer BA, Waldegger S, Heinzinger J, et al. KCNQ2 and KCNQ3 mutations contribute to different idiopathic epilepsy syndromes. Neurology 2008;71:177-183.
19. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007;4:18-61.
20. Benarroch EE. Potassium channels: Brief overview and implications in epilepsy. Neurology 2009;72:664-669.
21. Blackburn-Munro G, Jensen BS. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol 2003; 460:109-116.
22. Korsgaard MPG, Hartz BP, Brown WD, Ahring PK, Strobaek D, Mirza NR. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J Pharmacol Exp Ther 2005;314:282-292.
23. Dencker D, Dias R, Pedersen ML, Husum H. Effect of the new antiepileptic drug retigabine in a rodent model of mania. Epilepsy Behav 2008;12:49-53.
24. Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM; on behalf of the 205 Study Group. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007;68:1197-1204.
25. Commission on Classification and Terminology of ILAE. Proposal for revised clinical classification of epileptic seizures. Epilepsia 1981;22:489-501.
26. Barry MJ, Fowler FJ, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. Measurement Committee of the American Urological Association. J Urol 1992;148:1549-1557.
27. Number needed to treat (NNT). Bandolier 1999; 59(suppl). Available at: Http://www.medicine.ox.ac.uk/ bandolier/band59/NNT1.html. Accessed February 24, 2010.
28. Mohanraj R, Brodie MJ. Measuring the efficacy of antiepileptic drugs. Seizure 2003;12:413-443.
29. Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA; Pregabalin 1008-009 Study Group. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005;64:475-480.
30. Elger C, Halász P, Maia J, Almeida L, Soares-da-Silva P; BIA-2093-301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009;50:454-463.
31. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, et al.; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443-453.
32. Beyenburg S, Stavern K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: Systematic review and metaanalysis. Epilepsia 2010;51:7-26.
33. Johannessen SI, Ben-Menachem E. Management of focalonset seizures: An update on drug treatment. Drugs 2006; 66:1701-1725.
34. Tomson T, Walczak T, Sillanpaa M, Sander JW. Sudden unexpected death in epilepsy: A review of incidence and risk factors. Epilepsia 2005;46(suppl 11):54-61.
35. Streng T, Christoph T, Andersson KE. Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats. J Urol 2004;172:2054-2058.
36. Yeung SY, Pucovský V, Moffatt JD, et al. Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. Br J Pharmacol 2007;151:758-770.